SCHEMBL3473926

SCHEMBL3473926

CC1CCC(C(C)C)C(CCO)C1

nearest known ligand 0.52

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 3/20 0.52
TRPA1 O75762 2/20 0.52
EPHX1 P07099 3/20 0.44
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.35
OPRM1 P35372 1/20 0.35
KCNA5 P22460 1/20 0.34
TRPV1 Q8NER1 3/20 0.34
CYP19A1 P11511 2/20 0.34
KDM4E B2RXH2 1/20 0.34
APOBEC3A P31941 1/20 0.34
APOBEC3G Q9HC16 1/20 0.34
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4661828 0.89 TRPM8 (0.48) TRPM8TRPA1EPHX1ALDH1A1LMNA
SCHEMBL21380099 0.87 TRPM8 (0.47) TRPM8TRPA1EPHX1ALDH1A1LMNA
SCHEMBL26191694 0.84 TRPM8 (0.55) TRPM8TRPA1EPHX1ALDH1A1LMNA
SCHEMBL113450 0.84 TRPM8 (0.55) TRPM8TRPA1EPHX1ALDH1A1LMNA
SCHEMBL26191668 0.84 TRPM8 (0.55) TRPM8TRPA1EPHX1ALDH1A1LMNA
SCHEMBL7750544 0.84 TRPM8 (0.55) TRPM8TRPA1EPHX1ALDH1A1LMNA
SCHEMBL7747412 0.84 TRPM8 (0.55) TRPM8TRPA1EPHX1ALDH1A1LMNA
SCHEMBL7610579 0.82 TRPM8 (0.48) TRPM8TRPA1EPHX1ALDH1A1LMNA
SCHEMBL5501057 0.82 TRPM8 (0.48) TRPM8TRPA1EPHX1ALDH1A1LMNA
SCHEMBL28523754 0.81 TRPM8 (0.47) TRPM8TRPA1EPHX1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2014273-A1 Use of methyl methyl ether and another ether to provide a feeling of cleanliness and purity Symrise GmbH & Co. KG (DE) 2009-01-14 EP claimed
EP-1341512-B1 RHINOLOGICAL AGENTS SYMRISE GMBH & CO KG (DE) 2008-12-31 EP claimed
EP-1341512-A1 RHINOLOGICAL AGENTS HAARMANN & REIMER GMBH (DE) 2003-09-10 EP claimed
WO-2002041861-A1 RHINOLOGICAL AGENTS HAARMANN & REIMER GMBH (DE) 2002-05-30 WO claimed
CN-117481998-A Retinol substitutes in skin treatment 西姆莱斯有限公司 2024-02-02 CN disclosed
US-9445606-B2 Use of 4-hydroxydihydrochalcones and their salts for enhancing an impression of sweetness SYMRISE AG (DE) 2016-09-20 US disclosed
US-8574554-B2 Uses of 4-methyl-5-hydroxy-hexanoic acid lactone SYMRISE AG (DE) 2013-11-05 US disclosed
US-20100233102-A1 USE OF 4-HYDROXYDIHYDROCHALCONES AND THEIR SALTS FOR ENHANCING AN IMPRESSION OF SWEETNESS SYMRISE GMBH & CO. KG (DE) 2010-09-16 US disclosed
EP-2014273-A1 Use of methyl methyl ether and another ether to provide a feeling of cleanliness and purity Symrise GmbH & Co. KG (DE) 2009-01-14 EP disclosed
EP-1341512-B1 RHINOLOGICAL AGENTS SYMRISE GMBH & CO KG (DE) 2008-12-31 EP disclosed
US-20080242740-A1 AROMA COMPOSITIONS OF ALKAMIDES WITH HESPERETIN AND/OR 4-HYDROXYDIHYDROCHALCONES AND SALTS THEREOF FOR ENHANCING SWEET SENSORY IMPRESSIONS SYMRISE GMBH & CO. KG (DE) 2008-10-02 US disclosed
US-20080220140-A1 USE OF PROPENYLPHENYL GLYCOSIDES FOR ENHANCING SWEET SENSORY IMPRESSIONS SYMRISE GMBH & CO. KG (DE) 2008-09-11 US disclosed
US-20070297993-A1 Novel Use of Nonenolide SYMRISE GMBH & CO. KG (DE) 2007-12-27 US disclosed
EP-1868561-A1 MENTHOL-CONTAINING SOLIDS COMPOSITION Symrise GmbH & Co. KG (DE) 2007-12-26 EP disclosed
US-20070254826-A1 Novel uses of 4-methyl-5-hydroxy-hexanoic acid lactone SYMRISE GMBH & CO. KG (DE) 2007-11-01 US disclosed
EP-1793797-A1 USE OF EUGENOL ACETATE AS AN AGENT AGAINST BAD BREATH Symrise GmbH & Co. KG (DE) 2007-06-13 EP disclosed
WO-2006106130-A1 MENTHOL-CONTAINING SOLIDS COMPOSITION SYMRISE GMBH & CO. KG (DE) 2006-10-12 WO disclosed
WO-2006032666-A1 USE OF EUGENOL ACETATE AS AN AGENT AGAINST BAD BREATH SYMRISE GMBH & CO. KG (DE) 2006-03-30 WO disclosed
EP-1341512-A1 RHINOLOGICAL AGENTS HAARMANN & REIMER GMBH (DE) 2003-09-10 EP disclosed
WO-2002041861-A1 RHINOLOGICAL AGENTS HAARMANN & REIMER GMBH (DE) 2002-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242740-A1 AROMA COMPOSITIONS OF ALKAMIDES WITH HESPERETIN AND/OR 4-HYDROXYDIHYDROCHALCONES AND SALTS THEREOF FOR ENHANCING SWEET SENSORY IMPRESSIONS TAS2R5, TAS2R20, TAS2R40 TRPM8 266/4885TRPA1 343/4885EPHX1 650/4885
US-20070297993-A1 Novel Use of Nonenolide TAS2R14, TAS2R4, TAS2R7 TRPM8 561/4885TRPA1 137/4885EPHX1 1090/4885
US-20100233102-A1 USE OF 4-HYDROXYDIHYDROCHALCONES AND THEIR SALTS FOR ENHANCING AN IMPRESSION OF SWEETNESS TAS2R4, TAS2R1, TAS2R20 TRPM8 687/4885TRPA1 540/4885EPHX1 1560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.